Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6088312 | 0.90 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2GPBAR1MRGPRX4 | |
| SCHEMBL5725146 | 0.88 | CYSLTR1 (0.67) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL6089086 | 0.86 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2GPBAR1NR4A1NR4A2 | |
| SCHEMBL6091032 | 0.84 | NR4A2 (0.48) | CYSLTR1CYSLTR2GPBAR1NR4A1NR4A2 | |
| SCHEMBL6088658 | 0.82 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2GPBAR1MRGPRX4 | |
| SCHEMBL6088777 | 0.82 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL6088567 | 0.81 | NR4A2 (0.67) | NR4A1NR4A2NR4A3MRGPRX4 | |
| SCHEMBL6088614 | 0.81 | CYSLTR1 (0.50) | CYSLTR1CYSLTR2GPBAR1NR4A2 | |
| SCHEMBL6090336 | 0.80 | CYSLTR1 (0.58) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL6088680 | 0.80 | NR4A2 (0.62) | NR4A1NR4A2NR4A3MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |